Identifying the Best Predictive Biomarker in Pharmacogenomics Through Multiple Comparisons With the Best.

Area of Science:

• Pharmacogenomics
• Biostatistics
• Clinical Trial Analysis

Background:

• Single gene mutations, particularly single nucleotide polymorphisms (SNPs), are crucial clinical biomarkers for targeted therapies in areas like cancer and cardiovascular disease.
• Current methods for selecting the best SNP biomarker often fail to accurately differentiate between predictive (drug-SNP interaction) and prognostic (SNP main) effects, and lack robust ranking confidence intervals.

Purpose of the Study:

• To introduce a novel statistical method, Multiple Comparisons with the Best using Marginal Means (3M), for accurately identifying the best single SNP biomarker.
• To overcome the limitations of existing methods in distinguishing predictive from prognostic SNP effects and providing reliable ranking.

Main Methods:

• The 3M method calculates unbiased estimates of SNP predictive effects using marginal means (least squares means).
• It employs a nonparametric bootstrap method to construct simultaneous confidence intervals within the Multiple Comparisons with the Best framework to select the top predictive SNP.

Main Results:

• Simulation studies confirmed that 3M reliably distinguishes predictive from prognostic effects, demonstrating greater power in identifying the true best predictive SNP compared to existing approaches.
• Application to the IMPROVE-IT genome-wide association study data identified rs114462013 (STAG1) on chromosome 3 as the best predictive SNP.

Conclusions:

• The 3M method offers a more reliable and powerful approach for selecting the best predictive SNP biomarkers in pharmacogenomic studies.
• Accurate identification of predictive SNPs enhances the precision of therapeutic applications and clinical trial design.